8-K: Passage Bio Presents Positive Interim Data for FTD Gene Therapy at International Conference

Passage Bio's PBFT02 gene therapy shows promising interim safety and biomarker data in patients with frontotemporal dementia, demonstrating robust increases in progranulin levels.

Summary

• Passage Bio announced updated interim safety and biomarker data from their Phase 1/2 clinical trial, upliFT-D, for PBFT02, a gene therapy for frontotemporal dementia (FTD) caused by progranulin deficiency.
• The data, presented at the 14th International Conference on Frontotemporal Dementias, showed that PBFT02 was well-tolerated in all patients who received an enhanced immunosuppression regimen.
• PBFT02 treatment resulted in increased progranulin (PGRN) levels in the cerebral spinal fluid (CSF) in all patients, with up to a 6-fold increase at one month and up to a 10-fold increase at six months.
• CSF PGRN levels exceeded the range found in healthy adult controls and remained elevated at 12 months in one patient, reaching 34.2 ng/mL.
• Plasma PGRN expression remained below healthy reference levels across all patients.

Sentiment

Score: 8

Explanation: The document presents positive interim clinical data, indicating a potential breakthrough in FTD treatment. The safety profile and biomarker results are encouraging, leading to a positive sentiment.

Positives

• PBFT02 demonstrated a consistent increase in CSF progranulin levels across all patients.
• The therapy showed no serious adverse events in patients who received the enhanced immunosuppression regimen.
• There was no evidence of clinically significant immune response, hepatotoxicity, or safety-related imaging abnormalities.
• The rate of increase in CSF progranulin slowed between six and twelve months, suggesting a durable effect.
• The company has a strong cash position with runway expected to the end of 2Q 2026.

Negatives

• One patient experienced two serious adverse events with a lower level of immunosuppression, leading to a protocol amendment.
• Plasma progranulin levels did not increase, indicating the therapy's effect is primarily in the central nervous system.

Risks

• The company is dependent on collaborators and third parties for development and manufacturing.
• There are risks associated with clinical trials, including unexpected concerns and regulatory hurdles.
• The company faces the risk that positive results in early trials may not be replicated in later stages.
• There are risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

The company anticipates reporting 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025 and seeking regulatory feedback on pivotal trial design in the second half of 2025. They also plan to initiate dosing of FTD-C9orf72 patients in the first half of 2025 and obtain regulatory feedback on the pathway to treating ALS patients in the second half of 2024.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that they are very encouraged by the positive Cohort 1 data demonstrating robust and durable increases in CSF PGRN expression.
• He also noted that PBFT02 continued to be well-tolerated among all Cohort 1 patients who received enhanced immunosuppression.

Industry Context

This announcement is significant in the context of the broader industry trend of developing gene therapies for neurodegenerative diseases. The positive data for PBFT02 positions Passage Bio as a potential leader in the treatment of FTD, a disease with limited treatment options.

Comparison to Industry Standards

• The increase in CSF progranulin levels observed with PBFT02 is notable compared to other gene therapy approaches for neurodegenerative diseases.
• The sustained elevation of CSF progranulin for up to 12 months is a positive indicator of the therapy's potential durability.
• The safety profile of PBFT02, with no serious adverse events in patients receiving enhanced immunosuppression, is competitive with other gene therapy trials.
• The company's focus on a one-time treatment approach aligns with the industry's push for more convenient and effective therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical data.
• Patients with FTD and their families may have increased hope for a potential treatment.
• Employees of Passage Bio may be motivated by the positive results.
• The company's collaborators and partners may see increased value in their partnerships.

Next Steps

• The company will report 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025.
• They will seek regulatory feedback on pivotal trial design in the second half of 2025.
• The company plans to initiate dosing of FTD-C9orf72 patients in the first half of 2025.
• They will obtain regulatory feedback on the clinical pathway for treating ALS patients in the second half of 2024.

Key Dates

Keywords

gene therapy, frontotemporal dementia, FTD, progranulin, PGRN, PBFT02, neurodegenerative diseases, clinical trial, upliFT-D, CSF, AAV, biomarkers